This article is mentioned in:

Introduction

Hepatocellular carcinoma (HCC) is the most common type of malignant tumor and the leading cause of cancer-related mortality in the Guangxi Zhuang Autonomous Region of China (1). Epidemiological observations have shown that hepatitis B virus (HBV) infection and exposure to aflatoxin B1 are two major etiological risk factors for the high prevalence of HCC in this area (2–3). However, only a fraction of individuals who are hepatitis B surface antigen (HBsAg) carriers and have chronic aflatoxin exposure develop HCC later in life (4). The exact mechanism of hepatocarcinogenesis is not well understood and the risk factors for HCC require further investigation.

Interleukin-23 (IL-23) is an inflammatory hemopoietic cytokine comprised of a heterodimer of p40/p19, which shares a common p40 subunit with IL-12 (5). IL-23 is secreted predominantly by activated dendritic cells and phagocytic cells. Its main function is to induce T cells or dendritic cells to produce IL-17, IL-6 and IFN-γ. The IL-23 receptor (IL-23R) complex is comprised of IL-23R and IL-12Rβ1, which is also a component of the IL-12 receptor. IL-23R is highly expressed on the surface of T cells, monocyte cells and natural killer T cells, and has been identified to be involved in several chronic inflammatory diseases (6–7). The IL-23R gene is located on chromosome 1p31. Polymorphisms of the IL-23R gene have been reported to be associated with susceptibility to chronic inflammatory diseases, including inflammtory bowel disease (IBD) (8–9), psoriasis (10) and multiple sclerosis (11). IL-23R gene polymorphisms have been found to be associated with gastric cancer (12–13), esophageal cancer (14), colorectal carcinoma (15) and oral cancer (16), indicating that IL-23R gene polymorphisms may represent one of the genetic factors contributing to the regulation of the IL-23 signaling pathway and thus potentially modulating susceptibility to inflammatory cancers. HCC is a typical inflammation-associated malignancy and the pathological stage from hepatitis to HCC is a chronic inflammatory process (17). In the present study, a hospital-based case-control study was conducted to investigate whether IL-23R gene polymorphisms contribute to susceptibility to HBV-infected diseases in a Guangxi population in China.

Materials and methods

Study populations

The current study was designed as a retrospective study. The study consisted of 84 patients with HBV-related HCC (73 males and 11 females; mean age, 49.5 years old), 57 patients with HBV-induced liver cirrhosis (LC; 44 males and 13 females; mean age, 46.0 years old) and 87 patients with chronic hepatitis B (CHB; 74 males and 13 females; mean age, 40.3 years old). Patients with HBV-related HCC had not undergone previous radiotherapy or chemotherapy. All patients with HBV-infected disease were consecutively selected from the First Affiliated Hospital of Guangxi Medical University (Guangxi, China) between January and July 2011. Control subjects were matched to the patients on the basis of age and were selected accordingly from a group of 97 control subjects (71 males and 23 females; mean age, 42.0 years old). Control subjects underwent a routine medical check-up in the outpatient clinic of the Department of Internal Medicine (First Affiliated Hospital of Guangxi Medical University, Guangxi, China) between January and July 2011. According to thorough clinical and laboratory evaluation, there was no personal or family history of cancer or other serious diseases observed.

Following a period of at least 6 months with elevated alanine aminotransferase or aspartate aminotransferase (>40 IU/ml), CHB was defined as positive for HBsAg. LC was diagnosed based on pathological examinations or typical morphological observations from computed tomography (CT) or ultrasonography and laboratory features. In the HCC group, newly diagnosed HCC patients were included and patients with a medical history of HCC or other cancers were excluded. Diagnosis of HBV-related HCC was based on histological or cytological findings, or on elevated serum α-fetoprotein levels >400 ng/ml combined with at least one positive liver image on CT, magnetic resonance imaging or ultrasonography. All patients included were further confirmed as HBsAg-positive, HBV core antibody-positive and hepatitis B e antigen or hepatitis B e antibody-positive for at least six months. All subjects were Chinese from the Guangxi District and provided written informed consent. The study was approved by the ethics committee of the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

Single nucleotide polymorphism (SNP) selection and genotyping

rs10889677, rs1884444 and rs11465817 were selected as candidate SNPs for determining the association between IL-23R gene polymorphisms and HBV-infected patients, as earlier studies reported positive associations of these particular SNPs with specific inflammatory diseases and types of cancer (12). Venous blood from each patient was collected into vacutainer tubes containing EDTA and stored at 4°C. Amplification of the target DNA was performed by polymerase chain reaction (PCR). Primer sequences and reaction conditions are presented in Table I. The SNPs studied were genotyped by PCR-restriction fragment length polymorphism analysis. PCR products were visualized on a 2.0% agarose gel and stained with ethidium bromide (Promega Corporation, Madison, WI, USA) to detect the quality and the quantity of the amplified products. Digestion products were visualized on a 3.0% agarose gel and stained with ethidium bromide. Direct sequencing was also performed by Sangon Biotech Company (Shanghai, China) using randomly selected subjects (10% of all samples) to validate the method used in this study and the results were 100% concordant (Figs. 1–3).

Figure 1 Sequencing map of the genotype for the IL-23R rs10889677 polymorphism. Arrow in parts A-C indicates CC, AC and AA genotypes, respectively. IL-23R, interleukin-23 receptor.

Figure 3 Sequencing map of the genotype for the IL-23R rs11465817 polymorphism. Arrow in parts A-C indicates CC, AC and AA genotypes, respectively. IL-23R, interleukin-23 receptor.

Table I Primer sequences and reaction conditions for genotyping IL-23 gene polymorphisms.

Table I

Primer sequences and reaction conditions for genotyping IL-23 gene polymorphisms.

Polymorphism	Primer sequence	Ta, °C	Restriction enzyme	Product size, bp
rs10889677	F: 5′-AGGGGATTGCTGGGCCATAT-3′	61.0	MnII	A: 216
	R: 5′-TGTGCCTGTATGTGGACCA-3′			C: 154+62
rs1884444	F: 5′-TCTTAGGGAAAAATGTTATGCTTTTT-3′	56.0	HaeIII	T: 132
	R: 5′-GCATCCCATTGAATAGTGGC-3′			G: 106+26
rs11465817	F: 5′-CATTAAGTAAGAGATGAAAACTTTGG-3′	54.0	HaeIII	A: 136
	R: 5′-CTGTAGTGAGCTGTGACCATG-3′			C: 117+19

[i] T_a, annealing temperature.

Statistical analysis

Demographic and clinical data among groups were compared using a χ2 test for categorical variables and Student’s t-test for continuous variables. Hardy-Weinberg equilibrium was tested with a goodness of fit χ2 test with one degree of freedom to compare the observed genotype frequencies among the subjects with the expected genotype frequencies. Genotype and allele frequencies of IL-23R gene polymorphisms were compared among various groups using the χ2 test and Fisher’s exact test when appropriate, and odds ratios (OR) and 95% confidence intervals (CIs) were calculated by binary logistic regression and adjusted for age and gender to assess the relative risk conferred by a particular allele and genotype. The linkage disequilibrium (LD) between polymorphisms was quantified using Shi’s standardized coefficient D′ (18). Haplotypes and their frequencies were estimated based on a Bayesian algorithm using the Phase program (19). The SPSS 13.0 software package (SPSS, Inc., Chicago, IL, USA) was used for all statistical analysis. All tests were two-tailed. P<0.05 was considered to indicate a statistically significant difference.

Results

Clinical characteristics of the study participants

Results showed that the three candidate IL-23R genetic variants were in Hardy-Weinberg equilibrium in the patients and the control group. Demographic data of all subjects are presented in Table II. There was no statistically significant difference in age between the case and control groups. However, a significant difference was observed in gender distribution between the HCC patients and controls.

Table II Clinical characteristics of the study population.

Table II

Clinical characteristics of the study population.

Variable	Controls	CHB patients	LC patients	HCC patients
Overall	94	87	57	84
Gender, n (%)
Male	71 (75.5)	74 (85.1)	44 (77.2)	73 (86.9)
Female	23 (24.5)	13 (14.9)	13 (22.8)	11 (13.1)
P-valuea		0.109	0.816	0.054
Age (years)b	42.0±10.8	40.3±11.9	46.0±12.6	49.5±10.3
P-valuea		0.269	0.152	0.471

a Compared with controls and

b mean±SD.

{ label (or @symbol) needed for fn[@id='tfn4-mmr-08-02-0613'] } HCC, hepatocellular carcinoma; CHB, chronic hepatitis B; LC, liver cirrhosis.

Correlation between IL-23R polymorphisms and risk of CHB

Genotype and allele frequencies of the IL-23R rs10889677, rs1884444 and rs11465817 polymorphisms between CHB patients and healthy controls are presented in Table III. The genotype distributions of three polymorphisms between the CHB cases and healthy controls were in Hardy-Weinberg equilibrium. No significant differences were identified between the genotype and allele frequencies of the IL-23R rs10889677, rs1884444 and rs11465817 polymorphisms and CHB risk. Similarily, binary logistic regression analyses adjusted for age and gender did not reveal any significant difference between IL-23R rs10889677, rs1884444 and rs11465817 polymorphisms and CHB risk.

Table III Distribution of alleles and genotypes of three SNPs in the IL-23R gene and their association with CHB risk.

Table III

Distribution of alleles and genotypes of three SNPs in the IL-23R gene and their association with CHB risk.

Polymorphism	CHB patients, n=87 (%)	Control, n=94 (%)	Crude OR (95% CI)	Adjusted OR (95% CI)a	Adjusted P-valuea
rs10889677
Genotype
AA	57 (65.5)	55 (58.5)	1.00 (Ref)	1.00 (Ref)
AC	25 (28.7)	34 (36.2)	0.71 (0.38–1.34)	0.74 (0.39–1.40)	0.35
CC	5 (5.7)	5 (5.3)	0.97 (0.27–3.52)	0.93 (0.25–3.40)	0.91
Allele
A	139 (79.9)	144 (76.6)	1.00 (Ref)	1.00 (Ref)
C	35 (20.1)	44 (23.4)	0.82 (0.50–1.36)	0.83 (0.5–1.37)	0.46
rs1884444
Genotype
TT	45 (51. 7)	60 (63.8)	1.00 (Ref)	1.00 (Ref)
TG	33 (37.9)	24 (25.5)	1.83 (0.95–3.52)	1.82 (0.93–3.53)	0.08
GG	9 (10.3)	10 (10.6)	1.20 (0.45–3.20)	1.21 (0.45–3.24)	0.71
Allele
T	123 (70.7)	144 (76.6)	1.00 (Ref)	1.00 (Ref)
G	51 (29.3)	44 (23.4)	1.36 (0.85–2.17)	1.34 (0.83–2.14)	0.23
rs11465817
Genotype
AA	34 (39.1)	41 (43.6)	1.00 (Ref)	1.00 (Ref)
AC	41 (47.1)	34 (36.2)	1.45 (0.77–2.77)	1.39 (0.73–2.67)	0.32
CC	12 (13.8)	19 (20.2)	0.76 (0.32–1.79)	0.73 (0.31–1.75)	0.48
Allele
A	109 (62.4)	116 (61.7)	1.00 (Ref)	1.00 (Ref)
C	65 (37.4)	72 (38.3)	0.96 (0.63–1.47)	0.97 (0.63–1.49)	0.89

a Adjusted for age and gender by binary logistic regression model.

{ label (or @symbol) needed for fn[@id='tfn6-mmr-08-02-0613'] } HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence interval; IL-23R, interleukin-23 receptor; CHB, chronic hepatitis B; SNP, single nucleotide polymorphism.

Correlation between IL-23R polymorphisms and risk of LC patients

Genotype and allele frequencies of the IL-23R rs10889677, rs1884444 and rs11465817 polymorphisms between LC patients and healthy controls are presented in Table IV. Genotype distributions of three polymorphisms in the LC cases and healthy controls were in Hardy-Weinberg equilibrium. No significant differences were identified between the genotype and allele frequencies of the IL-23R rs10889677, rs1884444 and rs11465817 polymorphisms and LC risk. Similarily, binary logistic regression analyses adjusted for age and gender did not show any significant difference between IL-23R rs10889677, rs1884444 and rs11465817 polymorphisms and LC risk.

Table IV Distribution of alleles and genotypes of three SNPs in the IL-23R gene and their association with LC risk.

Table IV

Distribution of alleles and genotypes of three SNPs in the IL-23R gene and their association with LC risk.

Polymorphism	LC patients, n=57 (%)	Control, n=94 (%)	Crude OR (95% CI)	Adjusted OR (95% CI)a	Adjusted P-valuea
rs10889677
Genotype
AA	40 (70.2)	55 (58.5)	1.00 (Ref)	1.00 (Ref)
AC + CC	17 (29.8)	39 (41.5)	0.60 (0.30–1.21)	0.57 (0.28–1.16)	0.12
Allele
A	97 (85.1)	144 (76.6)	1.00 (Ref)	1.00 (Ref)
C	17 (14.9)	44 (23.4)	0.57 (0.31–1.06)	0.55 (0.30–1.03)	0.06
rs1884444
Genotype
TT	34 (59.6)	60 (63.8)	1.00 (Ref)	1.00 (Ref)
TG	15 (26.3)	24 (25.5)	1.10 (0.51–2.38)	1.10 (0.50–2.43)	0.81
GG	8 (14.0)	10 (10.6)	1.41 (0.51–3.92)	1.45 (0.51–4.12)	0.49
Allele
T	83 (72.8)	144 (76.6)	1.00 (Ref)	1.00 (Ref)
G	31 (27.5)	44 (23.4)	1.22 (0.72–2.08)	1.21 (0.70–2.08)	0.50
rs11465817
Genotype
AA	16 (28.1)	41 (43.6)	1.00 (Ref)	1.00 (Ref)
AC	28 (49.1)	34 (36.2)	2.11 (0.98–4.53)	1.96 (0.90–4.26)	0.09
CC	13 (22.8)	19 (20.2)	1.75 (0.70–4.36)	1.64 (0.65–4.15)	0.30
Allele
A	60 (52.6)	116 (61.7)	1.00 (Ref)	1.00 (Ref)
C	54 (47.4)	72 (38.3)	1.45 (0.91–2.32)	1.36 (0.84–2.20)	0.21

a Adjusted for age and gender by binary logistic regression model.

{ label (or @symbol) needed for fn[@id='tfn8-mmr-08-02-0613'] } HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence interval; IL-23R, interleukin-23 receptor; LC, liver cirrhosis; SNP, single nucleotide polymorphism.

Correlation between IL-23R polymorphisms and risk of HCC

Genotype and allele distributions of the IL-23R rs10889677, rs1884444 and rs11465817 polymorphisms between HCC patients and healthy controls are presented in Table V. The observed genotype frequencies for three variants were all in Hardy-Weinberg equilibrium in the case group and controls. Results showed no significant differences between the genotype and allele frequencies of the IL-23R rs10889677 and rs11465817 polymorphisms and HCC risk. However, in the rs1884444 polymorphism, the frequencies of the TT, TG and GG genotypes were 63.8, 25.5 and 10.6% in controls and were 45.2, 42.9 and 11.9% in case groups, respectively. The frequencies of the T and G alleles were 76.6 and 23.4% in controls, respectively and were 66.7 and 33.3% in case groups, respectively. The results indicated that there were significant differences in the genotype and allele frequencies of the IL-23R rs1884444 polymorphism between HCC patients and healthy controls. The rs1884444 TG genotype was associated with a significantly increased risk of HCC as compared with the TT genotype (OR, 2.37; 95% CI, 1.23–4.57; P=0.009). The rs1884444 G allele was associated with a significantly increased risk of HCC as compared with the T allele (OR, 1.64, 95% CI, 1.03–2.61; P=0.037). In the binary logistic regression analysis adjusted for age and gender, the results showed that the rs1884444 TG genotype was significantly associated with increased risk of HCC when compared with the TT genotype (adjusted OR, 2.86; 95% CI, 1.39–5.85; P=0.00). Similarily, the rs1884444 G allele was associated with a trend towards increased risk of HCC when compared with the T allele (adjusted OR, 1.58; 95% CI, 0.96–2.60; P=0.07); however, this difference was not significant.

Table V Distribution of alleles and genotypes of three SNPs in the IL-23R gene and their association with HCC risk.

Table V

Distribution of alleles and genotypes of three SNPs in the IL-23R gene and their association with HCC risk.

Polymorphism	HCC patients, n=84 (%)	Controls, n=94 (%)	Crude OR (95% CI)	Adjusted OR (95% CI)a	Adjusted P-valuea
rs10889677
Genotype
AA	55 (65.5)	55 (58.5)	1.00 (Ref)	1.00 (Ref)
AC	26 (31.0)	34 (36.2)	0.77 (0.41–1.44)	0.85 (0.43–1.67)	0.63
CC	3 (3.6)	5 (5.3)	0.60 (0.14–2.63)	0.66 (0.14–3.06)	0.60
Allele
A	136 (81.0)	144 (76.6)	1.00 (Ref)	1.00 (Ref)
C	32 (19.0)	44 (23.4)	0.77 (0.46–1.29)	0.83 (0.48–1.42)	0.50
rs1884444
Genotype
TT	38 (45.2)	60 (63.8)	1.00 (Ref)	1.00 (Ref)
TG	36 (42.9)	24 (25.5)	2.37 (1.23–4.57)	2.86 (1.39–5.85)	0.00
GG	10 (11.9)	10 (10.6)	1.58 (0.60–4.15)	1.24 (0.43–3.51)	0.69
Allele
T	112 (66.7)	144 (76.6)	1.00 (Ref)	1.00 (Ref)
G	56 (33.3)	44 (23.4)	1.64 (1.03–2.61)	1.58 (0.96–2.60)	0.07
rs11465817
Genotype
AA	42 (50.0)	41 (43.6)	1.00 (Ref)	1.00 (Ref)
AC	26 (31.0)	34 (36.2)	0.75 (0.38–1.46)	0.72 (0.34–1.50)	0.38
CC	16 (19.0)	19 (20.2)	0.82 (0.37–1.82)	0.99 (0.42–2.31)	0.97
Allele
A	110 (65.5)	116 (61.7)	1.00 (Ref)	1.00 (Ref)
C	58 (34.5)	72 (38.3)	0.85 (0.55–1.31)	0.92 (0.58–1.46)	0.72

a Adjusted for age and gender by binary logistic regression model.

{ label (or @symbol) needed for fn[@id='tfn10-mmr-08-02-0613'] } HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence interval; IL-23R, interleukin-23 receptor; SNP, single nucleotide polymorphism.

Haplotype analysis of IL-23R gene polymorphisms and HCC risk

Haplotype analyses were performed in HCC patients and healthy controls using the SHEsis software (18) and the possible eight haplotype frequencies are presented in Table VI. Moderate to minor LD was observed between the alleles of SNPs rs1884444 and rs11465817 (D′=0.164), rs1884444 and rs10889677 (D′=0.145) and rs11465817 and rs10889677 (D′=0.230). The results showed that the major ATA haplotype accounted for 41.1 and 41.0% of these eight haplotypes in the cases and the controls, respectively. Using haplotype analyses, the AGC haplotype was observed to be associated with a significantly increased risk of HCC as compared with the ATA haplotype (OR, 2.71; 95% CI, 1.06–6.93; P=0.03).

Table VI Frequencies of the haplotypes formed by rs10889677, rs1884444 and rs11465817 SNPs in HCC patients and controls.

Table VI

Frequencies of the haplotypes formed by rs10889677, rs1884444 and rs11465817 SNPs in HCC patients and controls.

Haplotype	HCC cases, 2n=168 (%)	Controls, 2n=188 (%)	OR (95% CI)	P-value
ATA	69 (41.1)	77 (41.0)	1.00 (Ref)
ATC	24 (14.3)	39 (20.7)	0.69 (0.38–1.26)	0.22
AGA	25 (14.9)	20 (10.6)	1.40 (0.71–2.73)	0.33
AGC	17 (10.1)	7 (3.7)	2.71 (1.06–6.93)	0.03a
CTA	10 (6.0)	13 (6.9)	0.86 (0.35–2.08)	0.74
CTC	8 (4.8)	15 (8.0)	0.60 (0.24–1.49)	0.26
CGA	7 (4.2)	6 (3.2)	1.30 (0.42–4.06)	0.65
CGC	8 (4.8)	11 (5.9)	0.81 (0.31–2.13)	0.67

a Compared with ATA haplotype.

{ label (or @symbol) needed for fn[@id='tfn12-mmr-08-02-0613'] } HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism.

Discussion

To the best of our knowledge, this is the first study to evaluate the association between the IL-23R gene polymorphisms and HCC risk in a Guangxi population in China. IL-23R rs1884444 T>G polymorphism was observed to be significantly associated with HCC. The rs1884444 TG genotype was associated with a significantly increased risk of HCC compared with the rs1884444 TT genotypes (adjusted OR, 2.37; 95%CI, 1.23–4.57; P=0.00). The rs1884444 G allele was associated with a trend towards an increased risk effect of HCC as compared with the T allele; however, this difference was not significant (adjusted OR, 1.58; 95% CI, 0.96–2.60; P=0.07). The haplotype AGC was associated with a significantly increased risk of HCC as compared with the major ATA haplotype (OR, 2.71; 95% CI, 1.06–6.93; P=0.03). These results indicate that the IL-23R rs1884444 T>G polymorphism increases HCC risk and may be used as genetic susceptibility markers for HCC.

Several epidemiological studies in diverse ethnic populations have previously been conducted and results consistent with the current study have not been observed. In the current study, the frequencies of the rs10889677 C, rs1884444 G and rs11465817 C alleles among the healthy controls were 0.234, 0.234 and 0.383, respectively, and these were similar to those frequencies observed in healthy Korean and Japanese populations (20,21); however, the frequencies were significantly lower than those of European Caucasians (0.689, 0.618 and 0.725, respectively) (22). In addition, the rs10889677 A>C, rs1884444 T>G and rs11465817 A>C polymorphisms were observed in moderate-to-minor LD. Major haplotype frequency of the ATA among the controls in the present study was 0.410, which was significantly higher than those of a study performed in Caucasians (0.213) (23), indicating that the distribution of IL-23R gene frequencies and haplotypes may vary among ethnic groups.

HCC is a typical inflammation-related malignancy (24). In addition, increasing evidence indicates that inflammation is important in the process of hepatocarcinogenesis (25–26). IL-23 is a member of the IL-12 cytokine family that stimulates memory CD4+ T cells to produce interferon-γ and to promote the development of distinctive Th17 cells (27). Studies have indicated that IL-23 may enhance the proliferation of memory T cells and the production of interferon-γ by activated T cells (5), indicating a role for IL-23 in cell-mediated antitumor immunity. IL-23R is the initial sensor of the IL-23 signal. It is also the determinant of Th17 cell expansion and in turn, serves as an important gate for the Th17-cell-mediated autoimmune responses. Due to the biological functions of IL-23R, this molecule has been hypothesized to be involved in the development of cancer and the associated complications. In agreement with this hypothesis, mice lacking IL-23 p19 display resistance to endogenous tumor formation when challenged in a chemical carcinogenesis protocol (28).

The IL-23R gene is located on chromosome 1p31. A number of studies have been conducted to investigate the associations between IL-23R gene polymorphisms and cancer risk (12,14,29). Chen et al(13) observed that the nonsynonymous SNP rs1884444 of the IL-23R gene may modify the risk of gastric cancer, particularly in intestinal types of gastric cancer. In addition, Zhang et al(29) previously indicated that IL-23R polymorphisms may be important in the susceptibility and prognosis of ovarian cancer and Chu et al(14) hypothesized that the IL-23R rs6682925 and rs1884444 variants affect esophageal cancer susceptibility through modulation of IL-23R biological activity. These results are consistent with the current data. In the current study, the rs1884444 TG genotype was associated with a significantly increased risk of HCC as compared with the TT genotype (adjusted OR, 2.37; 95%CI, 1.23–4.57; P=0.00). In the binary logistic regression analysis, rs1884444 G allele levels were insignificant when compared with the T allele (adjusted OR, 1.58; 95% CI, 0.96–2.60; P=0.07), which may be attributed to the fact that the limited sample size prevented the analysis from reaching a significant P-value. The rs1884444 T>G polymorphism is located at exon 2 of the IL-23R, which is responsible for the signal peptide of IL-23R(30). Thus far, the exact biological mechanism of the variant on HCC carcinogenesis has not been elucidated. Notably, according to the web-based SNP analysis tool, PupaSuite3, the T to G base change of rs1884444 may disrupt an exonic splicing enhancer, resulting in exon skipping, malformation or transcript alternative splicing. Another possible explanation is that this polymorphism results in an amino acid change in codon 3 (His>Gln) and may affect the ligand receptor binding specificity and affinity, modulating the pro-inflammatory effect by Th17 cells and may be involved in the development of HCC. However, these hypotheses are based on postulations or predictions and require confirmation by biological assays in future studies.

Haplotypes are a set of closely linked genetic markers present on one chromosome which tend to be inherited together and appear frequently in a block pattern owing to the presence of LD (31). In the current study, the AGC haplotype was observed to be significantly higher in the HCC patients than in controls when compared with the ATA haplotype (P=0.03). It is possible that a higher prevalence of the AGC haplotype in the IL-23R gene may modulate the expression of IL-23R, resulting in downregulation of the Th17 cell-mediated immune response and escape of tumor cells from immune surveillance. The current results indicate that the GCC haplotype of IL-23R gene may play a facilitative role in the development of HCC.

In summary, the rs1884444 polymorphism of the IL-23R gene was observed to be significantly correlated with the risk of HCC. These results indicate that the IL-23R gene may contribute to an inherited predisposition to HCC. Additional studies with larger sample sizes must be performed to confirm the current observations in diverse ethnic populations.

Abbreviations:

References